Webinar Technology

Part 1: Targeting Cancer Pathways: Tumor Resistance

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Part 1: Targeting Cancer Pathways: Tumor Resistance

Recorded 22 October 2014

Speakers

Downloads

Click here to register for this webinar subtitled in Chinese.

Brought to you by Science and Science Signaling.

This webinar is the first in a series (see Part 2 here) focusing on the pathways that allow for cancer development and progression, the emerging research in identifying and targeting these pathways, and the innovations in the development of cancer treatment options. Recent advances in our understanding of cancer have revealed that the disease cannot be understood through simple analysis of genetic mutations within cancerous cells. Instead, tumors should be considered complex tissues in which the cancer cells evolve and communicate with the surrounding cellular microenvironment to promote their own survival and dissemination. Although therapies against specific signaling proteins or pathways have been remarkably successful at treating certain cancers, the tumors frequently develop resistance, leading to even more aggressive forms of the disease.

This webinar will focus on how rewiring of signaling pathways in response to drug treatment contributes to resistance and how this knowledge can be leveraged to develop more effective treatment strategies.

During this webinar, viewers will:

  • Gain an understanding of the specific molecules and pathways that are the targets for rationally designed therapies
  • Learn about efforts to overcome resistance to the first FDA-approved therapy targeting a hyperactive kinase
  • Review mechanisms by which tumor cells resist inhibitors that target cell survival and growth pathways
  • Hear how the rewiring of cell death pathways can sensitize cells to traditional chemotherapy agents.

This webinar will last for approximately 60 minutes.

You can also view Part 2Part 3Part 4, and Part 5 of this series.

Speaker bios

Michael B. Yaffe, M.D., Ph.D.

Massachusetts Institute of Technology
Cambridge, MA

Dr. Yaffe is the David H. Koch Professor of Biology and Biological Engineering at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. He is also a senior associate member of the Broad Institute, and an attending surgeon/surgical intensivist in the Departments of Surgery and Anesthesia at Beth Israel Deaconess Medical Center, Harvard Medical School. Dr. Yaffe received his B.S. in materials science and engineering from Cornell University, and his M.D. and Ph.D. degrees from Case Western Reserve University, followed by advanced postdoctoral training with Prof. Lew Cantley at Harvard Medical School. Dr. Yaffe’s research focuses on the biology of the complex signaling pathways that cells use to respond to DNA damage and inflammation, particularly the role of protein kinases and modular binding domains in tumor development and anti-cancer therapeutics. His laboratory uses a multidisciplinary approach encompassing systems biology, molecular pharmacology, biochemistry/proteomics, cell and structural biology, and computation/bioinformatics. Dr. Yaffe is also the scientific editor-in-chief of Science Signaling and a member of the editorial boards of Molecular and Cellular Proteomics, and Cell Cycle.

Jeffrey Engelman, M.D., Ph.D.

Harvard Medical School
Boston, MA

Dr. Engelman is the principal investigator of his own laboratory at the Massachusetts General Hospital (MGH) Cancer Center, the director of thoracic oncology at MGH and the director of molecular therapeutics at the MGH Cancer Center. He received his B.A. in chemistry from Northwestern University and his M.D. and Ph.D. degrees from the Albert Einstein College of Medicine. Dr. Engelman completed his medical residency in internal medicine at Brigham and Women’s Hospital and his fellowship in hematology and oncology at the Dana-Farber Cancer Institute/MGH combined program. He joined the Harvard Medical School faculty and MGH in 2005. The research goal of his laboratory is to advance targeted therapies to benefit patients with cancer. His research focuses on understanding the biological underpinnings of sensitivity and resistance to specific kinase inhibitor targeted therapies in cancers with specific genetic abnormalities. In particular, his laboratory focuses on the regulation of key signaling networks that regulate cancer cell growth and survival. In his role as the director of thoracic oncology at MGH, he directs the research program of the thoracic oncology team. This program integrates laboratory studies, clinical trials, and comprehensive molecular analyses of cancers to pioneer individualized therapies. He has established a well-developed translational infrastructure that has culminated in a seamless bench-to-bedside connection with each activity informing the other.

Michael W. Deininger, M.D., Ph.D.

University of Utah
Salt Lake City, UT

Dr. Deininger is professor and chief of hematology and hematologic malignancies in the Department of Internal Medicine and the Huntsman Cancer Institute at the University of Utah. He also serves as senior director of transdisciplinary research at the Huntsman Cancer Institute. He has extensive experience treating patients with blood cancers and holds a particular interest in chronic myeloid leukemia and myeloproliferative neoplasms, a group of blood cancers related to leukemia. As a clinician-scientist with a translational research focus, Dr. Deininger is heading an extramurally funded research laboratory that is dedicated to the study of signaling pathways, drug resistance, and new molecular therapies in leukemia.

Annalisa VanHook, Ph.D.

Science Signaling/AAAS
Washington, DC

Dr. VanHook studied biology as an undergraduate at Kenyon College and received her Ph.D. from the Department of Human Genetics at the University of Utah.  She completed a postdoctoral fellowship at the University of California, Berkeley, supported by the Howard Hughes Medical Institute, in the field of evolutionary developmental biology. Dr. VanHook joined the staff of Science Signaling/AAAS in 2008, where she is currently web editor of Science Signaling.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here